Search
Cisplatin Treatment Options in United Kingdom
A collection of 298 research studies where Cisplatin is the interventional treatment. These studies are located in the United Kingdom . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-Small Cell Lung Cancer.
109 - 120 of 298
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Active Not Recruiting
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in:
* participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
* participants whose tumors express PD-L1 CPS ≥1
* all participants
The primary study hypotheses are that dCRT+ pembrolizumab is better t... Read More
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in:
* participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
* participants whose tumors express PD-L1 CPS ≥1
* all participants
The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:
* EFS in participants whose tumors express PD-L1 CPS ≥10
* EFS in participants whose tumors express PD-L1 CPS ≥1
* EFS in all participants
* OS in participants whose tumors express PD-L1 CPS ≥10
* OS in participants whose tumors express PD-L1 CPS ≥1
* OS in all participants Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691), Long Beach, California +169 locations
MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691), Long Beach, California
Columbus Regional Research Institute ( Site 0047), Columbus, Georgia
University of Kansas Cancer Center ( Site 0023), Westwood, Kansas
Cancer Center of Kansas ( Site 0058), Wichita, Kansas
University Medical Center ( Site 0035), New Orleans, Louisiana
Greater Baltimore Medical Center ( Site 0031), Baltimore, Maryland
Dana Farber Cancer Center ( Site 0034), Boston, Massachusetts
Henry Ford Hospital ( Site 0685), Detroit, Michigan
University of Missouri ( Site 0688), Columbia, Missouri
Renown Regional Medical Center ( Site 0706), Reno, Nevada
Rutgers Cancer Institute of New Jersey ( Site 0695), New Brunswick, New Jersey
Weill Cornell Medical College ( Site 0053), New York, New York
Stephenson Cancer Center ( Site 0044), Oklahoma City, Oklahoma
Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060), Portland, Oregon
Allegheny Health Network ( Site 0042), Pittsburgh, Pennsylvania
Thompson Cancer Survival Center ( Site 0696), Knoxville, Tennessee
Utah Cancer Specialists ( Site 0697), Salt Lake City, Utah
Cancer Care Northwest - Spokane Valley ( Site 0036), Spokane Valley, Washington
University of Wisconsin Hospital and Clinics ( Site 0033), Madison, Wisconsin
Instituto Medico Alexander Fleming ( Site 0063), Buenos Aires, Caba
Fundacion Favaloro ( Site 0061), Ciudad de Buenos Aires, Caba
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066), Buenos Aires, Not set
CEMIC ( Site 0064), Buenos Aires, Not set
UCL Saint Luc ( Site 0162), Brussels, Bruxelles-Capitale, Region De
UZ Gent ( Site 0163), Gent, Oost-Vlaanderen
UZ Leuven ( Site 0161), Leuven, Vlaams-Brabant
AZ Delta ( Site 0165), Roeselare, West-Vlaanderen
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088), Ijui, Rio Grande Do Sul
Hospital Nossa Senhora da Conceicao ( Site 0087), Porto Alegre, Rio Grande Do Sul
Clinica de Oncologia Reichow ( Site 0085), Blumenau, Santa Catarina
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081), Sao Paulo, Not set
Cross Cancer Institute ( Site 0010), Edmonton, Alberta
CancerCare Manitoba ( Site 0002), Winnipeg, Manitoba
The Ottawa Hospital - Cancer Care ( Site 0008), Ottawa, Ontario
Sunnybrook Research Institute ( Site 0012), Toronto, Ontario
Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005), Montreal, Quebec
Centro Investigación del Cáncer James Lind ( Site 0106), Temuco, Araucania
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103), Temuco, Araucania
Hospital Regional de Concepcion ( Site 0105), Concepcion, Biobio
Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104), Santiago, Region M. De Santiago
Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531), Hefei, Anhui
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si, Fuzhou, Fujian
The First Affiliated Hospital of Xiamen University ( Site 0538), Xiamen, Fujian
Hubei Cancer Hospital ( Site 0514), Wuhan, Hubei
Hunan Cancer Hospital ( Site 0515), Changsha, Hunan
Huai an First People s Hospital ( Site 0526), Huai An, Jiangsu
Jiangsu Cancer Hospital ( Site 0519), Nanjing, Jiangsu
The Affiliated Hospital of Xuzhou Medical University ( Site 0522), Xuzhou, Jiangsu
Affiliated Hospital of Jiangsu University ( Site 0524), Zhenjiang, Jiangsu
Jiangxi Cancer Hospital ( Site 0512), Nanchang, Jiangxi
Shanghai Chest Hospital ( Site 0503), Shangai, Shanghai
Shanghai Chest Hospital ( Site 0501), Shanghai, Shanghai
Zhongshan Hospital Fudan University ( Site 0502), Shanghai, Shanghai
Sichuan Cancer Hospital ( Site 0527), Chengdu, Sichuan
Tianjin Medical University Cancer Institute & Hospital ( Site 0505), Tianjin, Tianjin
Hangzhou First People's Hospital ( Site 0530), Hangzhou, Zhejiang
Sir Run Run Shaw Hospital ( Site 0523), Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 0529), Hangzhou, Zhejiang
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0721), Brno, Brno-mesto
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0719), Ostrava, Moravskoslezsky Kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0720), Olomouc, Olomoucky Kraj
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0718), Praha, Praha 5
Rigshospitalet ( Site 0199), Copenhagen, Hovedstaden
Odense Universitetshospital ( Site 0200), Odense, Syddanmark
SA Pohja-Eesti Regionaalhaigla ( Site 0201), Tallinn, Harjumaa
SA Tartu Ulikooli Kliinikum ( Site 0202), Tartu, Tartumaa
Institut De Cancerologie De Lorraine ( Site 0222), Vandoeuvre les Nancy, Ain
Centre Francois Baclesse ( Site 0236), Caen, Calvados
Centre Georges Francois Leclerc ( Site 0223), Dijon, Cote-d Or
CHU Limoges Hopital Dupuytren ( Site 0225), Limoges, Haute-Vienne
Institut Curie - Centre Rene Huguenin ( Site 0237), Saint-Cloud, Hauts-de-Seine
Institut Jean Godinot ( Site 0238), Reims, Marne
CHU Hotel Dieu Nantes ( Site 0230), Nantes, Pays-de-la-Loire
Institut Sainte Catherine ( Site 0228), Avignon, Provence-Alpes-Cote-d Azur
CHU Amiens Picardie Site Sud Amiens ( Site 0235), Amiens, Somme
CHD Vendee ( Site 0227), La Roche sur Yon, Vendee
Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253), Stuttgart, Baden-Wurttemberg
Universitaetsklinikum Koeln ( Site 0251), Koeln, Nordrhein-Westfalen
Universitaetsklinikum Muenster ( Site 0248), Muenster, Nordrhein-Westfalen
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247), Mainz, Rheinland-Pfalz
Charite Campus Virchow Klinikum ( Site 0250), Berlin, Not set
Facharztzentrum Eppendorf ( Site 0242), Hamburg, Not set
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122), Guatemala, Not set
Gastrosoluciones ( Site 0126), Guatemala, Not set
Oncomedica ( Site 0125), Guatemala, Not set
Grupo Medico Angeles ( Site 0121), Guatemala, Not set
Medi-K Cayala ( Site 0124), Guatemala, Not set
Centro Medico Integral De Cancerología (CEMIC) ( Site 0123), Quetzaltenango, Not set
Pamela Youde Nethersole Eastern Hospital ( Site 0543), Hong Kong, Not set
Princess Margaret Hospital. ( Site 0542), Hong Kong, Not set
Queen Mary Hospital ( Site 0541), Pokfulam, Not set
Pecsi Tudomanyegyetem AOK ( Site 0265), Pecs, Baranya
Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262), Gyula, Bekes
Orszagos Onkologiai Intezet ( Site 0263), Budapest, Not set
Debreceni Egyetem Klinikai Kozpont ( Site 0261), Debrecen, Not set
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300), Pavia, Lombardia
IRCCS Policlinico San Donato ( Site 0295), San Donato Milanese, Milano
Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294), Pisa, Toscana
ASST Papa Giovanni XXIII ( Site 0296), Bergamo, Not set
Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299), Cremona, Not set
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292), Milano, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Oncologia Clinica Sperimentale Addome ( Site 0, Napoli, Not set
IRCCS Istituto Oncologico Veneto ( Site 0298), Padova, Not set
Policlinico Universitario A. Gemelli ( Site 0297), Roma, Not set
Aichi Cancer Center Hospital ( Site 0563), Nagoya, Aichi
National Cancer Center Hospital East ( Site 0562), Kashiwa, Chiba
Kanagawa Cancer Center ( Site 0565), Yokohama, Kanagawa
Saitama Cancer Center ( Site 0564), Kitaadachi-gun, Saitama
Shizuoka Cancer Center Hospital and Research Institute ( Site 0566), Sunto-gun, Shizuoka
National Cancer Center Hospital ( Site 0561), Tokyo, Not set
Chonnam National University Hwasun Hospital ( Site 0625), Hwasun Gun, Jeonranamdo
National Cancer Center ( Site 0626), Goyang-si, Kyonggi-do
Asan Medical Center ( Site 0623), Songpagu, Seoul
Severance Hospital Yonsei University Health System ( Site 0624), Seoul, Not set
Samsung Medical Center ( Site 0622), Seoul, Not set
Korea University Guro Hospital ( Site 0621), Seoul, Not set
Cryptex Investigación Clínica S.A. de C.V. ( Site 0729), Cuauhtémoc, Ciudad De México, Distrito Federal
CENTRO HEMATO ONCOLOGICO PRIVADO-CHOP ( Site 0728), Toluca de Lerdo, Not set
Instituto Nacional de Enfermedades Neoplasicas ( Site 0141), Lima, Muni Metro De Lima
Detecta Clínica ( Site 0146), Surquillo, Muni Metro De Lima
Hospital Nacional Arzobispo Loayza ( Site 0143), Lima, Not set
Clinica San Gabriel ( Site 0142), Lima, Not set
Baguio General Hospital and Medical Center ( Site 0603), Baguio City, Benguet
Cebu Doctors University Hospital ( Site 0604), Cebu City, Cebu
The Medical City-Iloilo ( Site 0602), Iloilo City, Iloilo
St. Luke s Medical Center ( Site 0601), Quezon, National Capital Region
Hospital Beatriz Angelo ( Site 0374), Loures, Lisboa
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0372), Lisboa, Not set
Hospital da Luz ( Site 0373), Lisboa, Not set
CHLN Hospital Santa Maria ( Site 0376), Lisboa, Not set
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371), Porto, Not set
MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 0400), București, Bucuresti
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392), Cluj-Napoca, Cluj
S.C. Radiotherapy Center Cluj S.R.L ( Site 0391), Cluj-Napoca, Cluj
Ovidius Clinical Hospital OCH-Oncology and Hematology ( Site 0393), Ovidiu, Constanta
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394), Craiova, Dolj
Centrul Medical Topmed ( Site 0398), Targu-Mures, Mures
S.C.Focus Lab Plus S.R.L ( Site 0395), Bucuresti, Not set
GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430), Ufa, Baskortostan, Respublika
Kaluga Regional Clinical Oncology Center ( Site 0424), Kaluga, Kaluzskaja Oblast
Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421), Moscow, Moskva
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429), Moscow, Moskva
SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420), Samara, Samarskaya Oblast
Pavlov First Saint Petersburg State Medical University ( Site 0426), St. Petersburg, Sankt-Peterburg
Medical institute named after Berezin Sergey ( Site 0417), St. Petersburg, Sankt-Peterburg
Sverdlovsk Regional Oncology Hospital ( Site 0411), Ekaterinburg, Sverdlovskaya Oblast
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412), Kazan, Tatarstan, Respublika
Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643), Kaohsiung, Not set
China Medical University Hospital ( Site 0646), Taichung, Not set
Taichung Veterans General Hospital-Radiation Oncology ( Site 0647), Taichung, Not set
National Cheng Kung University Hospital ( Site 0645), Tainan, Not set
National Taiwan University Hospital ( Site 0641), Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644), Taipei, Not set
Chang Gung Medical Foundation. Linkou ( Site 0642), Taoyuan, Not set
Istanbul University Cerrahpasa Medical Faculty ( Site 0452), Istambul, Istanbul
Memorial Ankara Hastanesi ( Site 0461), Ankara, Not set
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0451), Istanbul, Not set
Ege Universitesi Tip Fakultesi ( Site 0457), Izmir, Not set
Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458), Izmir, Not set
Aberdeen Royal Infirmary ( Site 0474), Aberdeen, Aberdeen City
Cambridge University Hospitals NHS Trust ( Site 0477), Cambridge, Cambridgeshire
Royal Free Hospital ( Site 0702), London, England
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283), London, London, City Of
Hammersmith Hospital-Medical Oncology ( Site 0471), London, London, City Of
Nottingham University Hospitals NHS Trust ( Site 0476), Nottingham, Nottinghamshire
Royal Marsden Hospital (Sutton) ( Site 0281), Sutton, Surrey
University College Hospital NHS Foundation Trust ( Site 0701), London, Worcestershire
The Christie NHS Foundation Trust ( Site 0282), Manchester, Not set
Mount Vernon Hospital ( Site 0478), Northwood, Not set
Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Adenocarcinoma (EAC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Completed
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib \[TAGRISSO®\] failure) with T790M-negative mutation tumors, 2)... Read More
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib \[TAGRISSO®\] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status.
The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS.
Upon study completion, participants are discontinued and may be enrolled in a pembrolizumab extension study, if available. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Cedars-Sinai Medical Center ( Site 0070), Los Angeles, California +157 locations
Cedars-Sinai Medical Center ( Site 0070), Los Angeles, California
Pacific Cancer Care ( Site 0058), Monterey, California
UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0092), Orange, California
St. Joseph Heritage Healthcare ( Site 0003), Santa Rosa, California
North Shore University Health System ( Site 0030), Evanston, Illinois
Siouxland Regioinal Cancer Center dba June E. Nylen Cancer Center ( Site 0065), Sioux City, Iowa
Southdale Cancer Care, University of Minnesota Medical Center- Edina ( Site 0048), Edina, Minnesota
Saint Lukes Hospital of Kansas City ( Site 0060), Kansas City, Missouri
New York Oncology Hematology P.C ( Site 8000), Albany, New York
Monter Cancer Center ( Site 0054), Lake Success, New York
Memorial Sloan Kettering Cancer Center-Rockerfeller Patient Pavilion ( Site 0049), New York, New York
White Plains Hospital Center for Cancer Care ( Site 0014), White Plains, New York
Providence Portland Medical Center ( Site 0097), Portland, Oregon
Kaiser Permanente Northwest ( Site 0037), Portland, Oregon
Parkland Health & Hospital System ( Site 2102), Dallas, Texas
University of Texas Southwestern Medical Center at Dallas ( Site 0035), Dallas, Texas
Utah Cancer Specialists ( Site 0001), Salt Lake City, Utah
Emily Couric Clinical Cancer Center ( Site 0020), Charlottesville, Virginia
Froedtert Hospital & the Medical College of Wisconsin ( Site 0041), Milwaukee, Wisconsin
Chris OBrien Lifehouse ( Site 0200), Camperdown, New South Wales
Westmead Hospital ( Site 0201), Westmead, New South Wales
Eastern Health ( Site 0202), Box Hill, Victoria
Austin Health ( Site 0203), Heidelberg, Victoria
Liga Norte Riograndense Contra o Cancer ( Site 1909), Natal, Rio Grande Do Norte
Hospital de Caridade de Ijui ( Site 1907), Ijui, Rio Grande Do Sul
Hospital Bruno Born ( Site 1913), Lajeado, Rio Grande Do Sul
Hospital de Clinicas de Porto Alegre ( Site 1905), Porto Alegre, Rio Grande Do Sul
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1904), Porto Alegre, Rio Grande Do Sul
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 1911), Barretos, Sao Paulo
Hosp. Clinicas da Fac. de Medicina de Ribeirao Preto - USP ( Site 1912), Ribeirao Preto, Sao Paulo
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 1903), Sao Paulo, Not set
William Osler Health System ( Site 0100), Brampton, Ontario
Sunnybrook Health Sciences, Odette Cancer Centre ( Site 0102), Toronto, Ontario
Princess Margaret Cancer Centre ( Site 0104), Toronto, Ontario
Jewish General Hospital ( Site 0105), Montreal, Quebec
The First Affiliated Hospital of Anhui Medical University ( Site 0721), Hefei, Anhui
Cancer Hospital Chinese Academy of Medical Sciences ( Site 0717), Beijing, Beijing
Peking Union Medical College Hospital ( Site 0703), Beijing, Beijing
Beijing Cancer Hospital ( Site 0718), Beijing, Beijing
Southwest Hospital, The Third Military Medical University ( Site 0725), Chongqing, Chongqing
Fujian Cancer Hospital ( Site 0723), Fuzhou, Fujian
The Affiliated Tumour Hospital of Harbin Medical University ( Site 0706), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 0711), Zhengzhou, Henan
Xiangya Hospital of Central South University ( Site 0710), Changsha, Hunan
Hunan Cancer Hospital ( Site 0722), Changsha, Hunan
Jiangsu Cancer Hospital ( Site 0719), Nanjing, Jiangsu
The First Hospital of Jilin University ( Site 0702), Chang chun, Jilin
Jilin Cancer Hospital ( Site 0705), Changchun, Jilin
Shanghai Chest Hospital ( Site 0700), Shanghai, Shanghai
Zhongshan Hospital Fudan University ( Site 0712), Shanghai, Shanghai
Tangdu Hospital ( Site 0708), XI An, Shanxi
The First Affiliated Hospital of Xi an Jiaotong University ( Site 0709), XI An, Shanxi
Affiliated Tumor Hospital of Xinjiang Medical University ( Site 0701), Urumqi, Xinjiang
The First Affiliated Hospital.Zhejiang University ( Site 0713), Hangzhou, Zhejiang
Sir Run Run Shaw Hospital School of Medicine, Zhejiang University ( Site 0715), Hangzhou, Zhejiang
Zhejiang Cancer Hospital ( Site 0716), Hangzhou, Zhejiang
Centre Leon Berard ( Site 0801), Lyon, Auvergne
CHU Caen Service de Pneumologie ( Site 0804), Caen, Calvados
Centre Georges Francois Leclerc ( Site 0809), Dijon, Cote-d'Or
Hopital Jean Minjoz Besancon ( Site 0805), Besancon, Doubs
Hopital Prive d'Antony ( Site 0811), Antony, Hauts-de-Seine
C.H.U. de Tours - Hopital Bretonneau ( Site 0806), Tours, Indre-et-Loire
Centre D Oncologie de Gentilly ( Site 0810), Nancy, Meurthe-et-Moselle
Clinique Victor Hugo ( Site 0802), Le Mans, Sarthe
CHU Poitiers ( Site 0803), Poitiers, Vienne
Robert Bosch Krankenhaus Klinik Schillerhoehe ( Site 0904), Gerlingen, Baden-Wurttemberg
Universitaetsklinikum Mannheim ( Site 0911), Mannheim, Baden-Wurttemberg
Klinikum Wuerzburg Mitte gGmbH ( Site 0901), Wuerzburg, Bayern
Pius Hospital Oldenburg ( Site 0905), Oldenburg, Niedersachsen
Florence Nightingale Krankenhaus ( Site 0912), Duesseldorf, Nordrhein-Westfalen
Kliniken Essen-Mitte ( Site 0900), Essen, Nordrhein-Westfalen
Universitaetsklinikum Muenster ( Site 0906), Muenster, Nordrhein-Westfalen
Medizinische Fakultaet Carl Gustav Carus der TU Dresden ( Site 0907), Dresden, Sachsen
Asklepios Klinikum Hamburg ( Site 0908), Hamburg, Not set
Hong Kong Integrated Oncology Centre ( Site 0304), Hong Kong, Not set
Queen Mary Hospital ( Site 0301), Hong Kong, Not set
Queen Mary Hospital ( Site 0303), Hong Kong, Not set
Hong Kong United Oncology Centre ( Site 0306), Kowloon, Not set
Tuen Mun Hospital ( Site 0305), Tuen Mun, Not set
Barzilai Medical Center ( Site 1706), Ashkelon, HaDarom
Soroka Medical Center ( Site 1702), Beer-Sheva, HaDarom
Meir Medical Center ( Site 1701), Kfar-Saba, HaMerkaz
Rabin Medical Center ( Site 1704), Petah Tikva, HaMerkaz
Ha Emek Medical Center ( Site 1707), Afula, HaTsafon
Rambam Medical Center ( Site 1703), Haifa, Heifa
Chaim Sheba Medical Center. ( Site 1700), Ramat Gan, Tell Abib
Sourasky Medical Center ( Site 1705), Tel Aviv, Tell Abib
Istituto Europeo di Oncologia ( Site 1303), Milano, Lombardia
Ospedale San Vincenzo di Taormina ( Site 1302), Taormina, Messina
AOU San Luigi Gonzaga di Orbassano ( Site 1300), Orbassano, Torino
IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 1305), Bari, Not set
Azienda Ospedaliero Universitaria Careggi ( Site 1301), Firenze, Not set
Azienda Ospedaliera dei Colli V. Monaldi ( Site 1306), Napoli, Not set
Universita Campus Bio-Medico di Roma ( Site 1304), Roma, Not set
National Hospital Organization Nagoya Medical Center ( Site 0608), Nagoya, Aichi
Aichi Cancer Center Hospital ( Site 0612), Nagoya, Aichi
Fujita Health University Hospital ( Site 0619), Toyoake, Aichi
National Cancer Center Hospital East ( Site 0601), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 0616), Matsuyama, Ehime
Hyogo Cancer Center ( Site 0604), Akashi, Hyogo
Kanazawa University Hospital ( Site 0617), Kanazawa, Ishikawa
Kanagawa Cancer Center ( Site 0609), Yokohama, Kanagawa
Kansai Medical University Hospital ( Site 0606), Hirakata, Osaka
Shizuoka Cancer Center Hospital and Research Institute ( Site 0602), Sunto-gun, Shizuoka
National Hospital Organization Kyushu Medical Center ( Site 0621), Fukuoka, Not set
Kyushu University Hospital ( Site 0605), Fukuoka, Not set
Niigata Cancer Center Hospital ( Site 0610), Niigata, Not set
Okayama University Hospital ( Site 0614), Okayama, Not set
Osaka International Cancer Institute ( Site 0611), Osaka, Not set
National Cancer Center Hospital ( Site 0603), Tokyo, Not set
Toranomon Hospital ( Site 0615), Tokyo, Not set
Tokyo Metropolitan Komagome Hospital ( Site 0618), Tokyo, Not set
Wakayama Medical University Hospital ( Site 0613), Wakayama, Not set
Chungbuk National University Hospital ( Site 0404), Cheongju si, Chungcheongbuk-do [Chungbuk]
Gachon University Gil Medical Center ( Site 0408), Incheon, Incheon-gwangyeoksi [Incheon]
National Cancer Center ( Site 0400), Gyeonggi-do, Kyonggi-do
Seoul National University Bundang Hospital ( Site 0405), Seongnam-si, Kyonggi-do
Seoul National University Hospital ( Site 0402), Seoul, Seoul-teukbyeolsi [Seoul]
Asan Medical Center ( Site 0407), Seoul, Seoul-teukbyeolsi [Seoul]
Samsung Medical Center ( Site 0403), Seoul, Seoul-teukbyeolsi [Seoul]
The Catholic University of Korea. Seoul St. Mary s Hospital ( Site 0406), Seoul, Seoul-teukbyeolsi [Seoul]
Ulsan University Hospital ( Site 0401), Ulsan, Ulsan-Kwangyokshi
Instituto Jaliscience de Cancerologia ( Site 2000), Guadalajara, Jalisco
Medica Sur S.A.B de C.V. ( Site 2003), Mexico City, Not set
Oaxaca Site Management Organization SC ( Site 2001), Oaxaca, Not set
Instituto Nacional de Cancerologia. ( Site 2007), Tlalpan, Not set
Hospitalo Univ. Germans Trias i Pujol ( Site 1100), Badalona, Barcelona [Barcelona]
Hospital de la Santa Creu i Sant Pau ( Site 1102), Barcelona, Barcelona [Barcelona]
Hospital Universitari Vall d Hebron ( Site 1106), Barcelona, Barcelona [Barcelona]
Hospital Ramon y Cajal ( Site 1101), Madrid, Not set
Hospital Universitario 12 de Octubre ( Site 1103), Madrid, Not set
Complejo Hospitalario Carlos Haya de Malaga ( Site 1107), Malaga, Not set
Hospital Universitario Virgen Macarena ( Site 1104), Sevilla, Not set
Linkopings Universitetssjukhus ( Site 1504), Linkoping, Ostergotlands Lan [se-05]
Skanes Universitetssjukhus Lund ( Site 1503), Lund, Skane Lan [se-12]
Karolinska Universitetssjukhuset Solna ( Site 1500), Solna, Stockholms Lan [se-01]
Sahlgrenska Universitetssjukhuset ( Site 1502), Goteborg, Vastra Gotalands Lan [se-14]
Taipei Tzu Chi Hospital ( Site 0512), New Taipei City, New Taipei
Changhua Christian Hospital ( Site 0509), Changhua, Not set
National Taiwan University Hospital Hsin-Chu Branch ( Site 0511), Hsinchu, Not set
Hualien Tzu Chi Medical Center-Hospital ( Site 0510), Hualien, Not set
Kaohsiung Chang Gung Memorial Hospital ( Site 0507), Kaohsiung, Not set
Taipei Medical University Shuang Ho Hospital ( Site 0508), New Taipei, Not set
China Medical University Hospital ( Site 0505), Taichung, Not set
Taichung Veterans General Hospital ( Site 0504), Taichung, Not set
National Cheng Kung University Hospital ( Site 0506), Tainan, Not set
National Taiwan University Hospital ( Site 0500), Taipei, Not set
Mackay Memorial Hospital ( Site 0503), Taipei, Not set
Taipei Veterans General Hospital ( Site 0501), Taipei, Not set
Chang Gung Medical Foundation. Linkou ( Site 0502), Taoyuan, Not set
Sussex University Hospitals ( Site 1003), Brighton, Brighton And Hove
Western General Hospital ( Site 1009), Edinburgh, Edinburgh, City Of
Leicester Royal Infirmary ( Site 1000), Leicester, Leicestershire
University College London Hospitals NHS Foundation Trust ( Site 1006), London, London, City Of
Chelsea & Westminster Hospital ( Site 1001), London, London, City Of
Birmingham Heartlands Hospital ( Site 1002), Birmingham, Not set
St James s University Hospital ( Site 1008), Leeds, Not set
Barking Havering and Redbridge University Hospitals NHS Trust Queen s Hospital ( Site 1004), Romford, Not set
Conditions: Non-small Cell Lung Cancer
Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Active Not Recruiting
This is a phase II pilot trial of Paclitaxel Protein Bound and Gemcitabine based chemotherapy and the addition of Paricalcitol upon attainment of stable or progressive disease in eligible patients with untreated metastatic pancreatic ductal adenocarcinoma.
This is a phase II pilot trial of Paclitaxel Protein Bound and Gemcitabine based chemotherapy and the addition of Paricalcitol upon attainment of stable or progressive disease in eligible patients with untreated metastatic pancreatic ductal adenocarcinoma. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Barts Health NHS Trust, London, London, Greater
Barts Health NHS Trust, London, London, Greater
Conditions: Pancreatic Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Alaska Oncology and Hematology, LLC., Anchorage, Alaska +100 locations
Alaska Oncology and Hematology, LLC., Anchorage, Alaska
Beverly Hills Cancer Center, Beverly Hills, California
USC/Norris Comprehensive Cancer Center, Los Angeles, California
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California
UC Irvine Health, Orange, California
Stanford Cancer Institute, Stanford, California
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado
Georgetown University Medical Center, Washington, District of Columbia
Moffitt Cancer Center, Tampa, Florida
Northside Hospital Central Research Department, Atlanta, Georgia
Northwestern Memorial Hospital, Chicago, Illinois
Rush University Medical Center, Chicago, Illinois
Orchard Healthcare Research Inc., Skokie, Illinois
Kansas City Veterans Affairs Medical Center, Westwood, Kansas
Kansas City VA Medical Center, Kansas City, Missouri
Weill Cornell Medical/New York-Presbyterian Hospital, New York, New York
Great Lakes Cancer Care, Williamsville, New York
Wake Forest Baptist Health - High Point Medical Center, High Point, North Carolina
FirstHealth Outpatient Cancer Center, Pinehurst, North Carolina
University Hospital Cleveland Medical Center, Cleveland, Ohio
OSU Brain & Spine Hospital, Columbus, Ohio
Siouxland Regional Cancer Center dba June E. Nylen Cancer Center, North Sioux City, South Dakota
Southern Highlands Cancer Centre, Bowral, New South Wales
Saint Vincents Hospital Sydney, Darlinghurst, New South Wales
St George Private Hospital, Kogarah, New South Wales
Pindara Private Hospital, Benowa, Queensland
Sunshine Coast University Private Hospital, Birtinya, Queensland
Flinders Medical Centre, Bedford Park, South Australia
Ashford Cancer Centre Research, Windsor Gardens, South Australia
Peninsula Health - Frankston Hospital, Frankston, Victoria
Western Health - Sunshine Hospital, Melbourne, Victoria
Joondalup Health Campus, Joondalup, Western Australia
CIUSSS Saguenay Lac St-Jean, Quebec, Not set
McGill University Health Centre, Quebec, Not set
APHP - Hôpital Ambroise Paré, Boulogne-Billancourt, Not set
CHRU de Brest - Hopital Morvan, Brest, Not set
Centre Francois Baclesse, Caen, Not set
CHU de CAEN, Caen, Not set
Centre Jean Perrin - 58 rue Montalembert, Clermont-Ferrand, Not set
Centre Georges-François Leclerc, Dijon, Not set
Clinique Victor Hugo, Le Mans, Not set
Institut Curie, Paris, Not set
CHU de Bordeaux Hopital Haut leveque, Pessac, Not set
Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre Benite, Not set
Institut de Cancérologie de l'Ouest, Saint Herblain, Not set
Evangelische Lungenklinik Berlin Krakenhausbetriebs GmBH, Berlin, Not set
Klinikum Chemnitz gGmbH, Chemnitz, Not set
Universitatsklinikum Koln, Klinik I fur Innere Medizin, Cologne, Not set
Klinikum Esslingen GmbH, Klinik fur Kardiologie, Angiologie und Pneumologie, Esslingen, Not set
Universitatsklinikum Frankfurt, Frankfurt, Not set
Asklepios Fachkliniken Munchen-Gauting, Zentrum fur Pneumologie und Thoraxchirugie, Gauting, Not set
LungenClinic Grosshansdorf, Grosshansdorf, Not set
Martha-Maria Krankenhaus Halle Dölau gGmbH, Halle, Not set
LKI Lungenfachklinik Immenhausen, Immenhausen, Not set
Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Not set
Queen Elizabeth Hospital, Hong Kong, Not set
Queen Mary Hospital, Hong Kong, Not set
Hong Kong United Oncology Center, Kowloon, Not set
ASST Spedali Civili di Brescia, Brescia, Not set
AOU Policlinico Vittorio Emanuele - POG Rodolico, Catania, Not set
Azienda Ospedaliero-Universitaria di Parma, Parma, Not set
IRCCS Istituti Fisioterapicic Ospitalieri - Istituto Nazionale Tumori Regina Elena, Rome, Not set
IRCCS Instituto Clinico Humanitas, Rozzano, Not set
Chungbuk National University Hospital, Cheongju-si, Not set
Gachon University Gil Medical Center, Inchon, Not set
Asan Medical Center, Seoul, Not set
Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
The Catholic University of Korea St. Vincent's Hospital, Suwon, Not set
Sultan Ismail Hospital, Johor Bahru, Not set
Hospital Raja Perempuan Zainab II, Kota Bharu, Not set
Hospital Kuala Lumpur, Kuala Lumpur, Not set
University Malaya Medical Centre, Kuala Lumpur, Not set
Hospital Tengku Ampuan Afzan, Kuantan, Not set
Sarawak General Hospital, Kuching, Not set
Institut Kanser Negara, Putrajaya, Not set
Complejo Hospitalario Universitario A Coruna. Hospital Teresa Herrera, A coruna, Not set
Hospital Universitari Germans Trias i Pujol, Badalona, Not set
Hospital Universitari Vall d'Hebrón, Barcelona, Not set
Hospital Clinic de Barcelona, Barcelona, Not set
Hospital Duran i Reynals, Barcelona, Not set
Hospital General Universitario Gregorio Maranon, Madrid, Not set
Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Not set
Clinica Universidad de Navarra - Pamplona, Pamplona, Not set
Hospital Regional Universitario de Malaga-Hospital Civil, Rincon de la Victoria, Not set
Complejo Hospitalario Universitario de Santiago de Compostela CHUS_Hospital Clinico Universitario, Santiago de Compostela, Not set
Hospital Universitario Virgen de Valme, Sevilla, Not set
Hospital Universitario Virgen Macarena, Sevilla, Not set
Hospital Universitari i Politecnic La Fe, Valencia, Not set
Changhua Christian Hospital, Changhua City, Not set
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Not set
E-DA Hospital, Kaohsiung City, Not set
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set
Chi Mei Hospital - Liouying, Liouying Dist., Not set
National Cheng Kung University Hospital, Tainan City, Not set
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei City, Not set
National Taiwan University Hospital, Taipei City, Not set
Taipei Veterans General Hospital, Taipei, Not set
Chang Gung Memorial Hospital (CGMH), Taoyuan City, Not set
University Hospitals Birmingham NHS Foundation Trust, Birmingham, Not set
Guy's and St Thomas' NHS Foundation Trust, London, Not set
Conditions: Non-small Cell Lung Cancer
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Terminated
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +87 locations
Ironwood Cancer and Research Center, Chandler, Arizona
City of Hope, Duarte, California
UCLA Hematology/Oncology, Los Angeles, California
Stanford Cancer Institute, Palo Alto, California
Torrance Memorial Physician Network - Cancer Care Associates, Redondo Beach, California
Providence Medical Foundation, Santa Rosa, California
Memorial Healthcare System, Hollywood, Florida
Ocala Oncology Center, Ocala, Florida
University Center and Blood Center,LLC., Athens, Georgia
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Virginia Piper Cancer Center (Alliant Health, Minneapolis, Minnesota
Washington University of Medicine- Siteman Cancer Center, Saint Louis, Missouri
Astera Cancer Care, East Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai and the Mount Sinai Hospital, New York, New York
New York Cancer and Blood Specialists, Port Jefferson Station, New York
Sanford Roger Maris Cancer Center, Fargo, North Dakota
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Lancaster General Hospital, Lancaster, Pennsylvania
Medical University of South Carolina, Charleston, South Carolina
Avera Cancer Institute, Sioux Falls, South Dakota
MD Anderson Cancer Center, Houston, Texas
Huntsman Cancer Institute, Salt Lake City, Utah
St. Vincent's Hospital Sydney, Darlinghurst, New South Wales
Macquarie University, Macquarie Park, New South Wales
Blacktown Hospital, Westmead, New South Wales
Cairns Hospital, Cairns, Queensland
University of the Sunshine Coast, Sippy Downs, Queensland
Princess Alexandra Hospital, Woolloongabba, Queensland
Austin Health, Heidelberg, Victoria
Alfred Health, Melbourne, Victoria
ZiekenhuisNetwerk Antwerpen (ZNA) - Stuivenberg, Antwerpen, Not set
Algemeen Ziekenhuis Klina, Brasschaat, Not set
UZ Antwerpen, Edegem, Not set
Universitaire Ziekenhuis Leuven, Leuven, Not set
Centre Hospitalizer De L'Ardenne, Libramont-Chevigny, Not set
AZ Sint-Maarten, Mechelen, Not set
CHU UCL Namur - Sainte-Elisabeth, Namur, Not set
Institut Bergonie, Bordeaux, Not set
Centre Georges François Leclerc, Dijon, Not set
Centre Léon Bérard, Lyon, Not set
Hopital de la Timone, Marseille, Not set
Centre de Lutte Contre le Cancer (CLCC) - Centre Antoine Lacassagne (CAL) - Site Est, Nice, Not set
Institut Curie, Paris, Not set
Hopital Pitie-Salpetriere, Paris, Not set
Civils de Lyon-Centre Hopitalier Lyon Sud, Pierre-benite, Not set
Hopital Foch, Suresnes, Not set
Institut Gustave Roussy, Villejuif, Not set
Charite University Medicine, Berlin, Not set
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Bonn, Not set
Universitatsmedizin Gottingen, GÃttingen, Not set
Kath. Marienkrankenhaus gGmbH, Hamburg, Not set
Universitäres Krebszentrum Leipzig, Leipzig, Not set
Technische Universitat Munchen (TUM) - Klinikum Rechts der Isar, Munich, Not set
Queen Mary Hospital, Hong Kong, Not set
Princess Margaret Hospital, Lai Chi Kok, Not set
Azienda Ospedaliero - Universitaria di Bologna - IRCCS, Bologna, Not set
ASST degli Spedali Civili di Brescia, Brescia, Not set
Ospedale San Luca Luca, Lucca, Not set
Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Not set
Azienda Ospedaliero-Universitaria di Modena - Policlinico, Modena, Not set
Arcispedale Santa Maria Nuova, Reggio Emilia, Not set
Azienda Ospedaliero - Universitaria Senese, Siena, Not set
Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Not set
Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie, Panstwowy Instytut Badawczy, Oddzial x Gliwicach, Gliwice, Not set
Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Oddzial Onkologii Klinicznej i Immunookologii z Poddoddzialem Dziennym i Izba Przyjec, Poznan, Not set
Wojewodzki Szpital Specjalistyczny w Siedlcach, Siedlce, Not set
Narodowy Instytut Onkologii im. M. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Glowy i Szyi, Warsaw, Not set
Hospital de Braga, Braga, Not set
Centro Hospitalar do Algarve, Faro, Not set
Hospital CUF Descobertas, Lisboa, Not set
Unidade Local de Saude de Matosinhos EPE - Hospital Pedro Hispano SA, Matosinhos, Not set
Centro Hospitalar Universitario do Porto, Porto, Not set
Instituto Portugues de Oncologia Do Porto Francisco Gentil,E.P.E., Porto, Not set
Hospital Universitari Vall d'Hebron, Barcelona, Not set
Hospital del Mar, Barcelona, Not set
Hospital De La Santa Creu I Sant Pau, Barcelona, Not set
Hospital Universitario de Jaen, Jaen, Not set
Hospital General Universitario Gregorio Maranon, Madrid, Not set
MD Anderson Cancer Center, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Regional Universitario de Malaga, Malaga, Not set
Clinica Universidad de Navarra, Pamplona, Not set
Hospital Universitario Virgen Macarena, Sevilla, Not set
Hospital Universitario Virgen del Rocio, Sevilla, Not set
Hospital Universitari i Politecnic La Fe, Valencia, Not set
Hospital Clínico Universitario de Valencia, Valencia, Not set
Royal Marsden NHS Foundation Trust, Royal Marsden - Sutton, London, Not set
Musgrove Park Hospital, Taunton, Not set
Conditions: Head and Neck Squamous Cell Carcinoma
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Completed
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.
The overall primary efficacy hypotheses are as follows:
1. In participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors are programmed cell death-liga... Read More
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.
The overall primary efficacy hypotheses are as follows:
1. In participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors are programmed cell death-ligand 1 (PD-L1)-positive (defined as combined positive score \[CPS\] ≥10), ESCC participants whose tumors are PD-L1 positive (CPS ≥10), and in all participants, overall survival (OS) is superior with pembrolizumab plus SOC chemotherapy compared with placebo plus SOC chemotherapy.
2. In participants with ESCC, participants whose tumors are PD-L1 positive (CPS ≥10), and in all participants, progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator is superior with pembrolizumab plus SOC chemotherapy compared with placebo plus SOC chemotherapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Kaiser Permanente Southern California ( Site 0003), West Los Angeles, California +188 locations
Kaiser Permanente Southern California ( Site 0003), West Los Angeles, California
The University of Chicago Medical Center ( Site 0001), Chicago, Illinois
University of Kansas ( Site 0029), Westwood, Kansas
University of Maryland Medical Center ( Site 0013), Baltimore, Maryland
Dana Farber Cancer Center ( Site 0009), Boston, Massachusetts
Henry Ford Cancer Center ( Site 0018), Detroit, Michigan
Washington University School of Medicine ( Site 0031), Saint Louis, Missouri
Roswell Park Cancer Institute ( Site 0004), Buffalo, New York
Weill Cornell Medical College ( Site 0024), New York, New York
University Hospitals Cleveland Medical Center ( Site 0002), Cleveland, Ohio
UPMC Cancer Center/Hillman Cancer Center ( Site 0015), Pittsburgh, Pennsylvania
University of Tennessee Medical Center Knoxville ( Site 0017), Knoxville, Tennessee
Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0603), Viedma, Rio Negro
Hospital Aleman ( Site 0605), Buenos Aires, Not set
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0602), Buenos Aires, Not set
Sanatorio Allende - Cordoba ( Site 0604), Cordoba, Not set
Hospital Privado Centro Medico Cordoba ( Site 0601), Cordoba, Not set
Blacktown Hospital ( Site 2000), Blacktown, New South Wales
Liverpool Hospital. ( Site 2001), Liverpool, New South Wales
Princess Alexandra Hospital ( Site 2005), Woolloongabba, Queensland
Eastern Health ( Site 2002), Box Hill, Victoria
Peter MacCallum Cancer Centre ( Site 2003), Melbourne, Victoria
CETUS Hospital Dia Oncologia ( Site 0208), Belo Horizonte, Minas Gerais
Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0210), Recife, Pernambuco
Clinica de Hematologia e Oncologia Viver Ltda ( Site 0211), Santa Maria, Rio Grande Do Sul
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0209), Rio de Janeiro, RJ
Hospital Sao Vicente de Paulo ( Site 0204), Passo Fundo, RS
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0201), Porto Alegre, RS
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto. ( Site 0203), Sao Jose do Rio Preto, Sao Paulo
Hospital Alemao Oswaldo Cruz ( Site 0207), Sao Paulo, SP
Hospital de Clinicas de Porto Alegre ( Site 0200), Porto Alegre, Not set
Instituto do Cancer de Sao Paulo - ICESP ( Site 0206), Sao Paulo, Not set
Tom Baker Cancer Centre ( Site 0503), Calgary, Alberta
Cross Cancer Institute ( Site 0502), Edmonton, Alberta
CancerCare Manitoba ( Site 0500), Winnipeg, Manitoba
Juravinski Cancer Center ( Site 0508), Hamilton, Ontario
The Ottawa Hospital - Cancer Care ( Site 0501), Ottawa, Ontario
Princess Margaret Cancer Centre ( Site 0505), Toronto, Ontario
CISSS de la Monteregie-Centre ( Site 0504), Greenfield Park, Quebec
Jewish General Hospital ( Site 0507), Montreal, Quebec
Hospital Regional de Concepcion Dr. Guillermo Grant Benavente ( Site 1003), Concepcion, Not set
Pontificia Universidad Catolica de Chile ( Site 1001), Santiago, Not set
Hospital Clinico Universidad de Chile ( Site 1002), Santiago, Not set
Clinica Alemana de Temuco ( Site 1006), Temuco, Not set
Anhui Provincial Hospital ( Site 0106), Hefei, Anhui
The First Affiliated Hospital of Anhui Medical University ( Site 0112), Hefei, Anhui
Peking Union Medical College Hospital ( Site 0123), Beijing, Beijing
The First Affiliated Hospital of Xiamen University ( Site 0119), Xiamen, Fujian
Guangdong General Hospital ( Site 0103), Guangzhou, Guangdong
The Affiliated Tumour Hospital of Harbin Medical University ( Site 0102), Harbin, Heilongjiang
Tongji Medical College Huazhong University of Science and Technology ( Site 0109), Wuhan, Hubei
Hunan Cancer Hospital ( Site 0105), Changsha, Hunan
PLA Cancer Centre of Nanjing Bayi Hospital ( Site 0110), Nanjing, Jiangsu
Zhongda Hospital Southeast University ( Site 0125), Nanjing, Jiangsu
Jilin Cancer Hospital ( Site 0101), Changchun, Jilin
The First Affiliated Hospital of Xi an Jiaotong University ( Site 0120), Xi'an, Shannxi
Zhejiang Cancer Hospital ( Site 0116), Hangzhou, Zhejiang
Beijing Cancer Hospital ( Site 0100), Beijing, Not set
Fujian Provincial Cancer Hospital ( Site 0104), Fuzhou, Not set
Shanghai Chest Hospital ( Site 0111), Shanghai, Not set
Fudan University Shanghai Cancer Center ( Site 0108), Shanghai, Not set
Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0114), Shanghai, Not set
Henan Cancer Hospital ( Site 0107), Zhengzhou, Not set
Rodrigo Botero SAS ( Site 2703), Medellin, Antioquia
Oncomedica S.A. ( Site 2701), Monteria, Cordoba
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 2600), San Jose, Not set
Policlinico San Bosco ( Site 2602), San Jose, Not set
ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 2601), San Jose, Not set
Rigshospitalet ( Site 2301), Copenhagen, Not set
Odense Universitetshospital ( Site 2300), Odense, Not set
Centre Leon Berard ( Site 0307), Lyon, Cedex 8
CHU Brest - Institut de Cancerologie et d Hematologie ( Site 0305), Brest, Not set
Centre Francois Baclesse ( Site 0310), Caen, Not set
Centre Oscar Lambret ( Site 0304), Lille, Not set
Institut du Cancer de Montpellier ( Site 0306), Montpellier, Not set
CHU de Nantes - Hotel Dieu ( Site 0303), Nantes Cedex 1, Not set
Institut Mutualiste Montsouris ( Site 0300), Paris, Not set
CHU de Saint Etienne Hopital Nord ( Site 0309), Saint Etienne, Not set
Staedtisches Klinikum Dresden ( Site 1507), Dresden, Not set
Haematologisch-Onkologische Praxis Eppendorf Facharztzentrum Eppendorf - Hope ( Site 1502), Hamburg, Not set
Universitaetsklinikum Leipzig ( Site 1501), Leipzig, Not set
Klinikum Ludwigsburg ( Site 1509), Ludwigsburg, Not set
Universitatsklinikum Mannheim GmbH ( Site 1504), Mannheim, Not set
Klinik fuer Haematologie. Onkologie und Gastroenterologie ( Site 1508), Moenchengladbach, Not set
III. Medizinische Klinik Klinikum rechts der Isar ( Site 1506), Munchen, Not set
Centro de Investigacion Oncologica ( Site 1402), Guatemala, Not set
Oncomedica ( Site 1400), Guatemala, Not set
Grupo Medico Angeles ( Site 1401), Guatemala, Not set
Medi-K Cayala ( Site 1404), Guatemala, Not set
Centro Regional de Sub Especialidades Medicas SA ( Site 1403), Quetzaltenango, Not set
Humanity Health Research Centre ( Site 1603), Hong Kong, Not set
Pamela Youde Nethersole Eastern Hospital ( Site 1601), Hong Kong, Not set
Princess Margaret Hospital. ( Site 1602), Hong Kong, Not set
Queen Mary Hospital ( Site 1600), Hong Kong, Not set
Aichi Cancer Center Hospital ( Site 0902), Nagoya, Aichi
National Cancer Center Hospital East ( Site 0908), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 0901), Matsuyama, Ehime
Hokkaido University Hospital ( Site 0916), Sapporo, Hokkaido
Hyogo Cancer Center ( Site 0913), Akashi, Hyogo
Kobe City Medical Center General Hospital ( Site 0929), Kobe, Hyogo
Ibaraki Prefectural Central Hospital ( Site 0918), Kasama, Ibaraki
University of Tsukuba Hospital ( Site 0910), Tsukuba, Ibaraki
Kagawa University Hospital ( Site 0915), Kita-gun, Kagawa
St. Marianna University School of Medicine Hospital ( Site 0903), Kawasaki, Kanagawa
Kanagawa Cancer Center ( Site 0921), Yokohama, Kanagawa
Oita University Hospital ( Site 0930), Yufu, Oita
Kansai Medical University Hospital ( Site 0931), Hirakata, Osaka
Kindai University Hospital ( Site 0917), Osakasayama, Osaka
Osaka University Hospital ( Site 0911), Suita, Osaka
Osaka Medical College Hospital ( Site 0925), Takatsuki, Osaka
Saitama Cancer Center ( Site 0926), Kitaadachi-gun, Saitama
Shizuoka Cancer Center Hospital and Research Institute ( Site 0914), Sunto-gun, Shizuoka
Kyorin University Hospital ( Site 0905), Mitaka, Tokyo
Chiba University Hospital ( Site 0909), Chiba, Not set
Chiba Cancer Center ( Site 0900), Chiba, Not set
National Hospital Organization Kyushu Cancer Center ( Site 0906), Fukuoka, Not set
Kyushu University Hospital ( Site 0922), Fukuoka, Not set
Gifu University Hospital ( Site 0920), Gifu, Not set
Kumamoto University Hospital ( Site 0919), Kumamoto, Not set
Niigata Cancer Center Hospital ( Site 0924), Niigata, Not set
Osaka International Cancer Institute ( Site 0923), Osaka, Not set
Osaka General Medical Center ( Site 0912), Osaka, Not set
National Cancer Center Hospital ( Site 0907), Tokyo, Not set
The Cancer Institute Hospital of JFCR ( Site 0904), Tokyo, Not set
Keio University Hospital ( Site 0927), Tokyo, Not set
National Cancer Center ( Site 1304), Goyang-si, Gyeonggi-do
Chonnam National University Hwasun Hospital ( Site 1305), Hwasun Gun, Jeollanam Do
Seoul National University Cancer Hospital ( Site 1301), Seoul, Not set
Severance Hospital Yonsei University Health System ( Site 1302), Seoul, Not set
Asan Medical Center ( Site 1303), Seoul, Not set
Samsung Medical Center ( Site 1300), Seoul, Not set
Beacon International Specialist Centre ( Site 1803), Petaling Jaya, Selangor
Hospital Kuala Lumpur ( Site 1805), Kuala Lumpur, Not set
University Malaya Medical Centre ( Site 1802), Kuala Lumpur, Not set
Instituto Regional de Enfermedades Neoplasicas del Sur IRENSUR ( Site 1702), Arequipa, Not set
Hospital Nacional Guillermo Almenara Irigoyen ( Site 1701), Lima, Not set
Instituto Nacional de Enfermedades Neoplasicas ( Site 1705), Lima, Not set
S C Pelican Impex SRL ( Site 2403), Oradea, Bihor
S.C. Radiotherapy Center Cluj S.R.L ( Site 2407), Comuna Floresti, Cluj
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2404), Craiova, Dolj
S.C.Focus Lab Plus S.R.L ( Site 2401), Bucuresti, Sector 2
S C Oncocenter Oncologie Medicala S R L ( Site 2405), Timisoara, Timis
S.C.Gral Medical S.R.L ( Site 2406), Bucuresti, Not set
Spitalul Clinic Judetean De Urgenta Constanta ( Site 2402), Constanta, Not set
SBHCI RCOD of MHC RB ( Site 0407), Ufa, Republic Of Bashkortostan
Leningrad Regional Oncology Center ( Site 0405), Saint-Petersburg, Vsevolzhsk District
National Medical and Surgical Center n.a. N.I.Pirogov ( Site 0402), Moscow, Not set
N.N. Blokhin NMRCO ( Site 0401), Moscow, Not set
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0406), Saint-Petersburg, Not set
St Petersburg City Clinical Oncology Dispensary ( Site 0409), St. Petersburg, Not set
Tomsk Scientific Research Institute of Oncology ( Site 0403), Tomsk, Not set
Cancer Care Langenhoven Drive Oncology Centre ( Site 2501), Port Elizabeth, Eastern Cape
The Medical Oncology Centre of Rosebank ( Site 2506), Johannesburg, Gauteng
WITS Clinical Research CMJAH Clinical Trial Site ( Site 2500), Parktown, Gauteng
The Oncology Centre ( Site 2502), Durban, Kwa-Zulu Natal
Cape Town Oncology Trials Pty Ltd ( Site 2508), Cape Town, Western Cape
Outeniqua Cancercare Oncology Unit ( Site 2504), George, Western Cape
Clinton Oncology Centre ( Site 2505), Alberton, Not set
Hospital Universitario Central de Asturias ( Site 0708), Oviedo, Asturias
Hosp. Gral. Universitari Germans Trias i Pujol ( Site 0701), Badalona, Barcelona
Hospital Universitari Vall d Hebron ( Site 0702), Barcelona, Not set
Hospital Universitario Reina Sofia ( Site 0706), Cordoba, Not set
Hospital Ramon y Cajal ( Site 0703), Madrid, Not set
Hospital Universitario La Paz ( Site 0700), Madrid, Not set
Complejo Hospitalario Virgen De La Victoria ( Site 0705), Malaga, Not set
Chang Gung Med Foundation. Kaohsiung Branch ( Site 1906), Kaohsiung, Not set
Taipei Medical University Shuang Ho Hospital ( Site 1908), New Taipei, Not set
China Medical University Hospital ( Site 1904), Taichung, Not set
Kuang Tien General Hospital ( Site 1909), Taichung, Not set
National Cheng Kung University Hospital ( Site 1905), Tainan, Not set
Chi Mei Medical Center Liuying ( Site 1907), Tainan, Not set
National Taiwan University Hospital ( Site 1900), Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center ( Site 1902), Taipei, Not set
Chang Gung Medical Foundation. Linkou ( Site 1903), Taoyuan, Not set
Bumrungrad International Hospital ( Site 2203), Bangkok, Not set
Chulalongkorn Hospital ( Site 2201), Bangkok, Not set
Ramathibodi Hospital. ( Site 2202), Bangkok, Not set
Phramongkutklao Hospital ( Site 2205), Bangkok, Not set
Songklanagarind Hospital ( Site 2204), Songkla, Not set
Adana Sehir Hastanesi ( Site 0802), Adana, Not set
Ankara Sehir Hastanesi ( Site 0808), Ankara, Not set
Istanbul Medeniyet Universitesi Goztepe EAH ( Site 0807), Istanbul, Not set
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0804), Istanbul, Not set
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 0801), Istanbul, Not set
Medical Park Izmir Hastanesi ( Site 0800), Izmir, Not set
Inonu Universitesi Turgut Ozal Tip Merkezi ( Site 0803), Malatya, Not set
Lothian University Hospitals NHS Trust ( Site 1101), Edinburgh, Mid Lothian
St Luke's Cancer Centre ( Site 1102), Guildford, Not set
The Christie NHS Foundation Trust ( Site 1100), Manchester, Not set
Conditions: Esophageal Neoplasms
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Terminated
The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2024
Locations: The University of Alabama at Birmingham - Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama +287 locations
The University of Alabama at Birmingham - Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama
Banner MD Anderson Cancer Center, Gilbert, Arizona
University of Arizona Cancer Center, Tucson, Arizona
UC San Diego Moores Cancer Center, La Jolla, California
Regents of the University of California, San Francisco, California
UCSF, San Francisco, California
The Oncology Institute of Hope & Innovation, Whittier, California
University of Colorado at Denver and Health Sciences Center, Aurora, Colorado
Yale Cancer Center, New Haven, Connecticut
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia
Moffitt Cancer Center, Tampa, Florida
ASCLEPES Research Centers, Weeki Wachee, Florida
Columbus Regional Research Institute, Columbus, Georgia
IACT Health, John B. Amos Cancer Center, Columbus, Georgia
Inventa Center for Cancer Research At Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana
Ashland-Bellefonte Cancer Center, Ashland, Kentucky
Norton Cancer Institute, Louisville, Kentucky, Brownsboro Hospital Campus, Louisville, Kentucky
Massachusetts General Hospital, Boston, Massachusetts
Beth Israel Deaconess (BI Lahey)/Harvard Cancer Center, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
University South Hospital, Ann Arbor, Michigan
Henry Ford Health System, Detroit, Michigan
Karmanos Cancer institute, Detroit, Michigan
University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri
MidAmerica Cancer Care, Kansas City, Missouri
Washington University School of Medicine, Saint Louis, Missouri
Comprehensive Cancer Center of Nevada (Southern Hills) (USA), Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
NYU Langone Hospital-Long Island Oncology, Mineola, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
NYU Grossman School of Medicine, New York, New York
Wake Forest University School of Medicine, Winston-Salem, North Carolina
University of Cincinnati Medical Center, Cincinnati, Ohio
University Hospital Cleveland Medical Center, Cleveland, Ohio
Cleveland Clinic, Cleveland, Ohio
Ohio State University, Columbus, Ohio
University of Oklahoma Health Sciences Center- Stephenson Cancer Center, Oklahoma City, Oklahoma
Providence Portland Medical Center, Portland, Oregon
Gettysburg Cancer Center, Gettysburg, Pennsylvania
Fox Chase Cancer Center, Philadelphia, Pennsylvania
Medical University of South Carolina- Hollings Cancer Center, Charleston, South Carolina
MD Anderson, Houston, Texas
IHO Corporation/Utah Cancer Specialists, Salt Lake City, Utah
University of Virginia Medical Center, Charlottesville, Virginia
Hospital Aleman, Buenos Aires, Not set
Instituto Medico Especialazado Alexander Fleming, Buenos Aires, Not set
Clinica Universitaria Reina Fabiola, Cordoba, Not set
Instituto de Oncologia de Rosario, Santa Fe, Not set
Clinica Viedma, Viedma, Not set
Ashford Cancer Centre Research, Tennyson Centre, Adelaide, Not set
St Vincents Hospital, Darlinghurst, Not set
St Vincents Hospital Melbourne, Fitzroy, Not set
Peter MacCallum Cancer Centre, Melbourne, Not set
Wollongong Hospital, Wollongong, Not set
Princess Alexandra Hospital, Cancer Trials Unit, Woolloongabba, Not set
Klinische Abteilung fur Allgemeine HNO Universitatsklinik fur Hals-, Nasen- und Ohrenheilkunde, Graz, Not set
Landeskrankenhaus Salzburg, Salzburg, Not set
Universitätsklinik für Innere Medizin III der PMU, Salzburg, Not set
Medical University of Vienna, Department of Medicine I, Division of Oncology, Vienna, Not set
Cliniques universitaires Saint-Luc, Bruxelles, Not set
Grand Hopital de Charleroi, Charleroi, Not set
Universitair Ziekenhuis Antwerpen, Edegem, Not set
Universitair Ziekenhuis Gent UZ Gent, Gent, Not set
Hopital de Jolimont, Rue Ferrer, La Louvière, Not set
UZ Leuven, Radiotherapy & Oncology, Leuven, Not set
Centre Hospitalier de l'Ardenne (CHA), Libramont, Not set
CHU UCL Namur Site Sainte Elisabeth, Namur, Not set
A.Z. Nikolaas, Sint-Niklaas, Not set
GZA Sint-Augustinus, Wilrijk, Not set
Fundação Pio XII- Hospital de Cancer de Barretos, Rua Antenor Duarte Vilela, Barretos, Not set
Hospital de Caridade de Ijui, Avenida David Jose Martins, Ijuí, Not set
Liga Norte Riograndense Contra o Câncer, Avenida Miguel Castro, Natal, Not set
Centro Gaúcho Integrado, Rua Costa, Porto Alegre, Not set
Hospital Santa Rita Centro de Pesquisa Clínica Novos Tratamentos Em Câncer, Porto Alegre, Not set
Hospital Santa Rita, Centro de Pesquisa Clínica Novos Tratamentos Em Câncer, Porto Alegre, Not set
National Cancer Institute, Rio De Janeiro, Not set
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - FMABC - Faculdade de Medicina do ABC, Santo André, Not set
Hospital de Base de Sao Jose do Rio Preto, Av. Brigadeiro Faria Lima, São José Do Rio Preto, Not set
Instituto do Cancer do Estado de Sao Paulo (ICESP), São Paulo, Not set
Oswaldo Cruz German Hospital, São Paulo, Not set
London Regional Cancer Program, London Health Sciences Centre, London, Not set
CHU Montréal, Montreal, Not set
CIUSSS de l'Est de l'Ile de Montreal - Hopital Maisonneuve-Rosemont, Montreal, Not set
Hopital Maisonneuve-Rosemont, Montreal, Not set
CHU de Quebec-Université Laval, Québec, Not set
Sunnybrook Research Institute, Toronto, Not set
Beijing Cancer Hospital, Beijing, Not set
Peking Union Medical College Hospital, Beijing, Not set
Jilin Cancer Hospital, Changchun, Not set
Hunan Cancer Hospital, Changsha, Not set
Xiangya Hospital Central South University, Changsha, Not set
West China Hospital of Sichuan University, Chengdu, Not set
Fujian Cancer Hospital, Fuzhou, Not set
The 5th Affiliated Hospital of Sun yet-sen university, Guangdong, Not set
The 2nd Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Not set
Zhejiang Province Cancer Hospital, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Not set
Lin Yi Cancer Hospital, Shandong, Not set
Fudan University Shanghai Cancer Center, Shanghai, Not set
Shanghai Ninth People's Hospital, Shanghai, Not set
Shantou University Cancer Hospital, Shantou, Not set
Liaoning Cancer Hospital & institute, Shenyang, Not set
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set
Tongji Hospital/Tongji Medical College, Huazhong University of Science, Wuhan, Not set
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Not set
Henan Cancer Hospital, Zhengzhou, Not set
University Hospital hradec Kralové, Hradec Králové, Not set
Fakultni Nemocnice Ostrava, Ostrava-Poruba, Not set
Hospital Na Bulovce, Prague, Not set
KOC KNTB a.s. Zlín, Zlín, Not set
CHU Amiens Picardie - Hopital Sud, Amiens, Not set
Institut de Cancérologie de l Ouest (ICO), Angers, Not set
Institut Sainte Catherine, Avignon Cedex 9, Not set
Centre hospitalier Universitaire de Bordeaux, Bordeaux, Not set
CHRU de Brest Hopital Morvan, Brest, Not set
Centre Jean Perrin CLCC, Clermont Ferrand, Not set
CHU de Grenoble, Grenoble Cedex 9, Not set
Centre Guillaume Le Conquerant, le Havre, Not set
Clinique Victor Hugo, Le Mans, Not set
Centre hospitalier Libourne, Libourne, Not set
Centre Oscar Lambret, Lille, Not set
Hôpital du Scorff, Lorient, Not set
Centre Leon Berard, Lyon, Not set
Service d'Oncologie Médicale, CHU Timone, Marseille, Not set
Hôpital Nord Franche Comté, Montbeliard, Not set
Institut Regional du Cancer de Montpellier, Montpellier, Not set
LHopital prive du Confluent Nantes, Nantes Cedex 2, Not set
CCConcorde (GCS), Neuilly sur Seine, Not set
Centre Antoine Lacassagne, Nice, Not set
CHU Nimes, Nimes, Not set
Institut Curie, Paris, Not set
Centre Eugène Marquis, Rennes Cedex, Not set
Centre Henri Becquerel CLCC, Rouen Cedex, Not set
CHP Saint Gregoire FINESS, Saint Gregoire, Not set
Institut de Cancérologie de l'Ouest - Site Saint Herblain, Saint Herblain, Not set
ICANS, Strasbourg, Not set
Institut Claudius Regaud - IUCT-O, Toulouse, Not set
CHU de Tours, Tours, Not set
The Public Hospital L'Institut de Cancerologie de Lorraine, Vandoeuvre les Nancy, Not set
Institut Gustave Roussy - Service de radiotherapie, Villejuif, Not set
Evex Hospitals Oncology Center, Kutaisi, Not set
Academician Fridon Todua Medical Center-Ltd Research Institute of Clinical Medicine, Tbilisi, Not set
Cancer Research Cent 4, Tbilisi, Not set
Institute of Clinical Oncology, Tbilisi, Not set
JSC "Evex Hospitals", Tbilisi, Not set
LEPL First University Clinic of Tbilisi State Medical University, Tbilisi, Not set
New Hospitals, Tbilisi, Not set
Simon Khechinashvili University Clinic, Tbilisi, Not set
CAMPUS CHARITÉ MITTE, Klinik f.Strahlentherapie, Berlin, Not set
Charité - Universitätsmedizin Berlin Campus Virchow, Berlin, Not set
Strahlenklinik des Uni-Klinikums, Erlangen, Not set
Department of radiation oncology, University Hospital Essen, Essen, Not set
Univesitätsklinikum Essen (AöR) Klinikum und Poliklinik für Strahlentherapie, Essen, Not set
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Not set
Universitaetsklinikum Jena - Klinik fuer Hals - Nasen und Ohrenheilkunde HNO, Jena, Not set
University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Not set
Universitatsklinikum Leipzig AoR, Klinik für Strahlentherapie, Leipzig, Not set
Universitaetsmedizin Mannheim UMM, Klinik fuer Hals-Nasen-Ohrenheilkunde Kopf- und Halschirurgie, Mannheim, Not set
Universitaetsklinikum Regensburg, Regensburg, Not set
Universitaetsmedizin Rostock, Rostock, Not set
Agioi Anargiroi General Oncology Hospital of Kifissia, Athens, Not set
Attikon University Hospital, Athens, Not set
Theagenio Anticancer Hospital, Thessaloníki, Not set
Orszagos Onkologiai Intezet Sugarterapias Osztaly, Budapest, Not set
Uzsoki Utcai Korhaz Onkologiai Osztaly, Budapest, Not set
Petz Aladár Megyei Kórház Onkoradiológiai Osztály, Győr, Not set
Pecsi Tudomanyegyetem Klinikai Kozpont Onkoterapias Intazet, Pécs, Not set
Szegedi Tudományegyetem ÁOK Onkoterápiás Klinika, Szeged, Not set
Rambam Healthcare Campus, Haifa, Not set
Research Fund of the Hadassah Medical Organization, Jerusalem, Not set
Rabin Medical Center, Petach Tiqva, Not set
Sheba Medical Center, Ramat Gan, Not set
Centro di Riferimento Oncologico, Aviano, Not set
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia, Brescia, Not set
Istituto di Candiolo IRCCS, Candiolo, Not set
Azienda Sanitaria Ospedaliera Santa Croce e Carle - Oncologia Medica -Ospedale Carle, Cuneo, Not set
Azienda Ospedaliero-Universitaria Careggi, Firenze, Not set
IRCCS AOU San Martino, Genova, Not set
Ospedale "Vito Fazzi" Lecce, Lecce, Not set
Az. USL 6 Ospedali Riuniti-Ospedale di Livorno, Livorno, Not set
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Not set
IRCCS-Istituto Europeodi Oncologia The European Institute of Oncology IEO, Milan, Not set
Istituto Nazionale dei Tumori, Milan, Not set
Policlinico di Modena, Modena, Not set
AORN Ospedale dei Monaldi, Napoli, Not set
AOU "Luigi Vanvitelli", Napoli, Not set
Istituto Nazionale Tumori (INT) IRCCS Fondazione "G. Pascale", Napoli, Not set
Istituto Oncologico Veneto Irccs, Padova, Not set
Azienda Ospedaliero Universitaria di Parma, Parma, Not set
Fondazione Policlinico Universitario Agostino Gemelli, Rome, Not set
ASL2_Presidio Ospedaliero San Paolo, Savona, Not set
National Cancer Center Hospital East, Chiba, Not set
National Cancer Center Hospital, Chuo-ku Tokyo, Not set
Saitama Medical University International Medical Center, Hidaka, Not set
Hyogo Cancer Center, Hyogo, Not set
University Hospital Kyoto Prefectural University of Medicine, Kamigyo-ku, Not set
Tokai University Hospital, Kanagawa, Not set
Hokkaido University Hospital, Kita-Ku, Not set
Okayama University Hospital, Kita-ku, Not set
Kobe University Hospital, Kobe, Not set
Cancer Institute Hospital of JFCR, Koto-ku, Not set
National Hospital Organization Shikoku Cancer Center, Matsuyama, Not set
Shizuoka Cancer Center, Nagaizumi-cho, Not set
Osaka International Cancer Institute, Osaka, Not set
Tokyo Medical University Hospital, Tokyo, Not set
Pusan National University Hospital, Busan, Not set
National Cancer Center Hematologic Oncology, Goyang-si, Not set
National Cancer Center, Goyang-si, Not set
Asan Medical Center, Asian Cacer Center, Seoul, Not set
Asan Medical Center, Seoul, Not set
KonKuk University Medical Center, Seoul, Not set
Korea University Anam Hospital, Seoul, Not set
Seoul National University Boramae Medical Center, Seoul, Not set
Pusan National University Yangsan Hospital, Oncol & Hematology, Yangsan, Not set
Uniwersyteckie Centrum Kliniczne - Klinika Onkologii i Radioterapii, Gdańsk, Not set
Szpitale Pomorskie Sp. z o.o., Gdynia, Not set
Centrum Onkologii- Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach, Gliwice, Not set
SP ZOZ MSWiA z W-M CO w Olsztynie, Olsztyn, Not set
NZOZ Provita Prolife Centrum Medyczne, Łódź, Not set
Centro Clinico Academico, Braga, Not set
Hospital de Braga, Braga, Not set
Instituto Português de Oncologia de Coimbra Francisco Gentil, EPE, Coimbra, Not set
Centro Hospitalar Universitário do Algarve - Hospital de Faro (PRT), Faro, Not set
Centro Hospitalar Universitário Lisboa Norte, Lissabon, Not set
Centro Hospitalar de Vila Nova de Gaia/Espinho, Porto, Not set
Centro Hospitalar Universitario São João, Porto, Not set
Hospital Pedro Hispano, Porto, Not set
Instituto Portugues de Oncologia Porto Francisco Gentil, E.P.E, Porto, Not set
State Autonomous Healthcare Institution "Republican Clinical Oncological Dispensary of the Ministry of Healthcare of the Republic of Tatarstan", Kazan, Not set
Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I.Kryzhanovsky, Krasnoyarsk, Not set
Kursk Regional Clinical Oncology Dispensary, Kursk, Not set
FGBU N.N.Blokhin Russian Cancer Research Center, Moscow, Not set
EuroCityClinic, Saint Petersburg, Not set
Saint- Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology), Saint Petersburg, Not set
FSBI National Med Research Cancer Center N.N. Petrov, Saint-Petersburg, Not set
Republican Clinical Oncological Dispensary of Bashkortostan, Ufa, Not set
State Budgetary Healthcare Institution Republican Clinical Oncology Dispensary (RUS), Ufa, Not set
State Budgetary Institution of Healthcare of Yaroslavl region Clinical oncology hospital, Yaroslavl, Not set
Fundacion Centro Oncologico de Galicia (COG) "Jose Antonio Quiroga y Pineyro", A Coruña, Galicia
Fundacin Oncolgico de Galicia Jos Antonio Quiroga y Pieyro, A Coruna, Not set
Hospital Clinic Barcelona, Barcelona, Not set
Hospital del Mar, Barcelona, Not set
Hospital Universitari Vall d'Hebron, Barcelona, Not set
Institut Català d'Oncologia Badalona, Barcelona, Not set
Institut Català d'Oncologia, Hospital Duran, Barcelona, Not set
Institut Universitari Dexeus-Quiron (ESP), Barcelona, Not set
Hospital Reina Sofía, Cordoba, Not set
Institut Català d'Oncologia, Girona, Not set
Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Not set
Clinica Universidad de Navarra, Madrid, Not set
Hospital 12 de Octubre, Madrid, Not set
Hospital Clinico San Carlos, Madrid, Not set
Hospital Ramon y Cajal, Madrid, Not set
Hospital Universitario HM Sanchinarro, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Althaia, Xarxa Assistencial, Manresa, Not set
Fundacio Althaia, Manresa, Not set
Hospital Civil (Hospital Regional Universitario), Málaga, Not set
Clinica Universidad de Navarra, Pamplona, Not set
Hospital Universitario Marqués de Valdecilla. Santander, Santander, Not set
Fundacion Investigacion Hospital General Universitario de Valencia FiHgU (ESP), Valencia, Not set
Hospital Universitario La Fe, Valencia, Not set
IVO, Valencia, Not set
Inselspital, Bern University Hospital, Universitätsklinik für Radio-Onkologie, Bern, Not set
Hopitaux Universitaires de Geneve, Geneve, Not set
Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Not set
Chang-Gung Memorial Hospital-Kaohsiung, Kaohsiung City, Not set
Kaohsiung Medical University Memorial Hospital, Kaohsiung, Not set
Taichung Veterans General Hospital, Taichung City, Not set
China Medical University Hospital, Taichung, Not set
National Taiwan University Hospital, Taipei, Not set
Taipei Veterans General Hospital (VGHTP), Taipei, Not set
Chang Gung Medical Foundatoin Linkou Chang Gung Memorial Hospital, Taoyuan City, Not set
Medical center ASKLEPION LLC, Khodosivka, Not set
Kiev City Clinical Oncology Centre, Kiev, Not set
Medical center of Yuriy Spizhenko, Soborna Vulytsia, Kyiv, Not set
Aberdeen Royal infirmary, Dept. of Oncology, Aberdeen, Not set
Royal Marsden NHS Foundation Trust, Chelsea, Not set
NHS Greater Glasgow and Clyde, Glasgow, Not set
Royal Surrey County Hospital, Guildford, Not set
Charing Cross Hospital, London, Not set
The Christie NHS Foundation Trust, Manchester, Not set
Mount Vernon Cancer Centre, Northwood, Not set
Nottingham University Hospitals NHS Trust, Nottingham, Not set
University Hospital Southampton NHS Foundation Trust, Southampton, Not set
The Royal Marsden NHS Foundation Trust - Sutton, Sutton, Not set
Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Not set
Conditions: Squamous Cell Carcinoma of the Head and Neck
WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer
Completed
This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer. The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment.
This trial is to determine what dose of a drug called AZD1775 can safely be given in combination with cisplatin before surgery and with chemo-radiotherapy after surgery in patients with Head and Neck Cancer. The Investigators will also get some preliminary information regarding the effectiveness of this combined treatment. Read Less
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/03/2024
Locations: University Hospital Birmingham Nhs Foundation Trust, Birmingham, West Midlands +5 locations
University Hospital Birmingham Nhs Foundation Trust, Birmingham, West Midlands
Beatson West of Scotland Cancer Centre, Glasgow, Not set
St. James' University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, Not set
The Royal Marsden Hospital, London, Not set
University College London Hospitals, London, Not set
Clatterbridge Cancer Centre, Wirral, Not set
Conditions: Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
Terminated
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Not set, Alexandria, Louisiana +86 locations
Not set, Alexandria, Louisiana
Not set, Albuquerque, New Mexico
Not set, Dallas, Texas
Not set, Houston, Texas
Not set, Rosario, Santa Fe
Not set, Ciudad Autonoma de Buenos Aires, Not set
Not set, Bruxelles, Not set
Not set, Edegem, Not set
Not set, Gent, Not set
Not set, Salvador, BA
Not set, Porto Alegre, RS
Not set, Barretos, SP
Not set, Ribeirão Preto, SP
Not set, São Paulo, SP
Not set, São Paulo, SP
Not set, Belo Horizonte, Not set
Not set, Fortaleza, Not set
Not set, Ijuí, Not set
Not set, Porto Alegre, Not set
Not set, Pleven, Not set
Not set, Vratsa, Not set
Not set, Osijek, Not set
Not set, Zagreb, Not set
Not set, Tallinn, Not set
Not set, Tallinn, Not set
Not set, Essen, Not set
Not set, Budapest, Not set
Not set, Budapest, Not set
Not set, Győor, Not set
Not set, Nyíregyháza, Not set
Not set, Pécs, Not set
Not set, Szeged, Not set
Not set, Székesfehérvár, Not set
Not set, Tel Aviv, Not set
Not set, Ancona, Not set
Not set, Candiolo, Not set
Not set, Milano, Not set
Not set, Modena, Not set
Not set, Potenza, Not set
Not set, Reggio Emilia, Not set
Not set, Rimini, Not set
Not set, Chihuahua, Not set
Not set, Mexico City, Not set
Not set, Oaxaca, Not set
Not set, Szczecin, Not set
Not set, Warszawa, Not set
Not set, Aveiro, Not set
Not set, Coimbra, Not set
Not set, Lisboa, Not set
Not set, Porto, Not set
Not set, Baia Mare, Not set
Not set, Cluj-Napoca, Not set
Not set, Craiova, Not set
Not set, Iasi, Not set
Not set, Barnaul, Not set
Not set, Krasnodar, Not set
Not set, Moscow, Not set
Not set, Pyatigorsk, Not set
Not set, Saint Petersburg, Not set
Not set, Saint Petersburg, Not set
Not set, Saint-Petersburg, Not set
Not set, Groenkloof Pretoria, Gauteng
Not set, Pretoria, Gauteng
Not set, Durban, KZN
Not set, Cape Town, Western Cape
Not set, Sabadell, Barcelona
Not set, Barcelona, Not set
Not set, Barcelona, Not set
Not set, Barcelona, Not set
Not set, Madrid, Not set
Not set, Madrid, Not set
Not set, Madrid, Not set
Not set, Madrid, Not set
Not set, Madrid, Not set
Not set, Cherkassy, Not set
Not set, Chernivtsiy, Not set
Not set, Dnepropetrovsk, Not set
Not set, Donetsk, Not set
Not set, Kharkiv, Not set
Not set, Kyiv, Not set
Not set, Lutsk, Not set
Not set, Lviv, Not set
Not set, Sumy, Not set
Not set, Uzhgorod, Not set
Not set, Zaporizzhya, Not set
Not set, Rhyl, Wales
Not set, London, Not set
Conditions: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Completed
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS).
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and neck squamous cell carcinoma (LA HNSCC). The primary hypothesis is that pembrolizumab in combination with CRT is superior to placebo in combination with CRT with respect to event-free survival (EFS). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: UCLA Medical Center ( Site 0273), Los Angeles, California +150 locations
UCLA Medical Center ( Site 0273), Los Angeles, California
University of California San Francisco ( Site 0274), San Francisco, California
St. Joseph Heritage Healthcare ( Site 0254), Santa Rosa, California
Smilow Cancer Hospital at Yale New Haven ( Site 0256), New Haven, Connecticut
Rush University Medical Center ( Site 0260), Chicago, Illinois
Indiana University ( Site 0264), Indianapolis, Indiana
Mary Bird Perkins Cancer Center at St. Tammany Parish Hospital ( Site 0281), Baton Rouge, Louisiana
University of Massachusetts Memorial Medical Center ( Site 0285), Worcester, Massachusetts
University of Michigan Hospital and Health Systems ( Site 0267), Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute ( Site 0272), Detroit, Michigan
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center ( Site 0290), Springfield, Missouri
St. Vincent Healthcare Frontier Cancer Center ( Site 0286), Billings, Montana
Comprehensive Cancer Centers of Nevada ( Site 8004), Las Vegas, Nevada
University of Rochester - James P. Wilmot Cancer Center ( Site 0255), Rochester, New York
Oncology Hematology Care, Inc. ( Site 8003), Cincinnati, Ohio
Willamette Valley Cancer Institute and Research Center ( Site 8000), Eugene, Oregon
St. Luke's Cancer Center - Anderson ( Site 0251), Easton, Pennsylvania
St. Francis Hospital Cancer Center ( Site 1461), Greenville, South Carolina
Texas Oncology-Arlington North ( Site 8005), Arlington, Texas
Texas Oncology-Austin Central ( Site 8002), Austin, Texas
Texas Oncology PA ( Site 8001), Longview, Texas
University of Virginia Health System ( Site 0261), Charlottesville, Virginia
Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0269), Seattle, Washington
Medical Oncology Associates (Summit Cancer Centers) ( Site 0257), Spokane, Washington
Liverpool Hospital ( Site 0301), Liverpool, New South Wales (Australia)
Blacktown Hospital Western Sydney Local Health District ( Site 0304), Blacktown, New South Wales
Princess Alexandra Hospital ( Site 0305), Brisbane, Queensland
Royal Brisbane and Women s Hospital ( Site 0302), Herston, Queensland
Royal Adelaide Hospital ( Site 0303), Adelaide, South Australia
Peter MacCallum Cancer Centre ( Site 0300), Melbourne, Victoria
Landeskrankenhaus - Universitatsklinikum Graz ( Site 0601), Graz, Not set
Krankenhaus der Barmherzigen Schwestern Linz ( Site 0603), Linz, Not set
Landeskrankenhaus Salzburg ( Site 0600), Salzburg, Not set
Allgemeines Krankenhaus der Stadt Wien ( Site 0602), Vienna/Wien, Not set
Cliniques Universitaires Saint Luc - Bruxelles ( Site 0651), Brussels, Not set
UZ Gent ( Site 0650), Gent, Not set
UZ Leuven Campus Gasthuisberg ( Site 0652), Leuven, Not set
C.H.U. Sart Tilman-Service d'Oncologie Medicale ( Site 0654), Liege, Not set
Clinique et Maternite Sainte-Elisabeth ( Site 0653), Namur, Not set
Hospital Santa Izabel - Santa Casa de Misericordia da Bahia ( Site 0006), Salvador, Bahia
Centro Regional Integrado de Oncologia ( Site 0002), Fortaleza, Ceara
Liga Norte Riograndense Contra o Cancer ( Site 0005), Natal, Rio Grande Do Norte
Hospital Nossa Senhora da Conceicao ( Site 0001), Porto Alegre, Rio Grande Do Sul
Hospital de Clinicas de Porto Alegre ( Site 0011), Porto Alegre, RS
Fundacao Pio XII - Hospital de Cancer de Barretos ( Site 0003), Barretos, Sao Paulo
Instituto do Cancer de Sao Paulo - ICESP ( Site 0004), Sao Paulo, SP
Hospital das Clinicas da FMUSP de Ribeirao Preto ( Site 0008), Ribeirao Preto, Not set
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0010), Rio de Janeiro, Not set
Tom Baker Cancer Centre ( Site 0063), Calgary, Alberta
Cross Cancer Institute ( Site 0064), Edmonton, Alberta
Juravinski Cancer Centre ( Site 0062), Hamilton, Ontario
London Health Sciences Centre ( Site 0055), London, Ontario
The Ottawa Hospital - Cancer Care ( Site 0052), Ottawa, Ontario
Princess Margaret Cancer Centre ( Site 0051), Toronto, Ontario
McGill University Health Centre ( Site 0061), Montreal, Quebec
CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0057), Sherbrooke, Quebec
Hospital Pablo Tobon Uribe ( Site 0151), Medellin, Antioquia
Fundacion Valle del Lili ( Site 0150), Cali, Valle Del Cauca
Centro Medico Imbanaco de Cali S.A ( Site 0156), Cali, Valle Del Cauca
Centro de Investigacion Clinica del Country ( Site 0155), Bogota, Not set
FN Brno. ( Site 0703), Brno, Not set
Fakultni Nemocnice Hradec Kralove ( Site 0705), Hradec Kralove, Not set
Fakultni nemocnice Olomouc ( Site 0701), Olomouc, Not set
Fakultni nemocnice Ostrava ( Site 0702), Ostrava, Not set
Nemocnice Na Bulovce ( Site 0700), Praha 8, Not set
2. LF UK a FN Motol ( Site 0704), Praha, Not set
Centre Jean Bernard Laboratoire Mahe Meziani ( Site 0760), Le Mans, Not set
Clinique Francois Chenieux ( Site 0757), Limoges, Not set
Institut Claudius Regaud ( Site 0754), Toulouse Cedex 09, Not set
Institut De Cancerologie De Lorraine ( Site 0758), Vandoeuvre les Nancy, Not set
Institut Gustave Roussy ( Site 0759), Villejuif, Not set
Universitätsklinikum Erlangen ( Site 0801), Erlangen, Not set
SRH Waldklinikum Gera GmbH ( Site 0802), Gera, Not set
Universitares Cancer Center Hamburg - UCCH ( Site 0811), Hamburg, Not set
Medizinische Hochschule Hannover ( Site 0807), Hannover, Not set
Universitaetsklinikum Schleswig-Holstein-Campus Luebeck ( Site 0803), Luebeck, Not set
Klinikum der Universitaet Munchen ( Site 0810), Munchen, Not set
Universitaetsklinik Ulm ( Site 0804), Ulm, Not set
Rambam MC ( Site 0903), Haifa, Not set
Hadassah Ein Karem Jerusalem ( Site 0902), Jerusalem, Not set
Rabin Medical Center ( Site 0904), Petah Tikva, Not set
Sheba MC ( Site 0901), Ramat Gan, Not set
Tel Aviv Sourasky Medical Center ( Site 0900), Tel Aviv, Not set
Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0954), Modena, MO
Azienda Ospedaliero Universitaria Careggi ( Site 0955), Firenze, Not set
Istituto Nazionale Tumori ( Site 0950), Milano, Not set
Istituto Europeo di Oncologia ( Site 0953), Milano, Not set
Azienda Ospedaliera San Paolo ( Site 0952), Milano, Not set
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0951), Napoli, Not set
Istituto Oncologico Veneto ( Site 0957), Padova, Not set
Fondazione IRCCS - Policlinico San Matteo ( Site 0960), Pavia, Not set
National Cancer Center Hospital East ( Site 0350), Kashiwa, Chiba
Hokkaido University Hospital ( Site 0351), Sapporo, Hokkaido
Hyogo Cancer Center ( Site 0354), Akashi, Hyogo
Kagawa University Hospital ( Site 0359), Kita-gun, Kagawa
Miyagi Cancer Center ( Site 0353), Natori, Miyagi
Chiba Cancer Center ( Site 0358), Chiba, Not set
Hiroshima University Hospital ( Site 0352), Hiroshima, Not set
Osaka International Cancer Institute ( Site 0355), Osaka, Not set
Medical Hospital, Tokyo Medical And Dental University ( Site 0356), Tokyo, Not set
The Cancer Institute Hospital of JFCR ( Site 0357), Tokyo, Not set
Chungbuk National University Hospital ( Site 0454), Cheongju si, Chungcheongbuk Do
Seoul National University Bundang Hospital ( Site 0453), Seongnam-si, Gyeonggi-do
Chungnam National University Hospital ( Site 0455), Daejeon, Not set
Severance Hospital Yonsei University Health System ( Site 0452), Seoul, Not set
Samsung Medical Center ( Site 0450), Seoul, Not set
Noordwest Ziekenhuisgroep NWZ ( Site 1350), Alkmaar, Not set
VU Medisch Centrum ( Site 1352), Amsterdam, Not set
UMCG ( Site 1351), Groningen, Not set
UMC St. Radboud ( Site 1356), Nijmegen, Not set
Erasmus University Medical Center ( Site 1354), Rotterdam, Not set
Capital & Coast District Health Board - Wellington Hospital ( Site 0400), Wellington, Newtown
Dolnoslaskie Centrum Onkologii. ( Site 1001), Wroclaw, Dolnoslaskie
Mazowiecki Szpital Onkologiczny ( Site 1015), Wieliszew, Mazowieckie
Beskidzkie Centrum Onkologii im. Jana Pawla II ( Site 1005), Bielsko-Biala, Not set
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1007), Gdynia, Not set
Centrum Onkologii. Instytut im. Marii Sklodowskiej-Curie ( Site 1010), Gliwice, Not set
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 1008), Krakow, Not set
Zachodniopomorskie Centrum Onkologii ( Site 1013), Szczecin, Not set
Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie ( Site 1000), Warszawa, Not set
H.U. Vall de Hebron ( Site 1052), Barcelona, Not set
Hospital Duran i Reynals ( Site 1053), Hospitalet de Llobregat, Not set
Hospital Doce de Octubre ( Site 1054), Madrid, Not set
Hospital Universitario Ramon y Cajal ( Site 1055), Madrid, Not set
Hospital Clinico San Carlos ( Site 1051), Madrid, Not set
Hospital Universitario Virgen de la Victoria ( Site 1056), Malaga, Not set
Hospital Gral Universitario de Valencia ( Site 1050), Valencia, Not set
Chang Gung Medical Foundation - Kaohsiung ( Site 0501), Kaohsiung, Not set
Taichung Veterans General Hospital ( Site 0506), Taichung, Not set
National Cheng Kung University Hospital ( Site 0503), Tainan, Not set
National Taiwan University Hospital ( Site 0500), Taipei, Not set
MacKay Memorial Hospital ( Site 0505), Taipei, Not set
Taipei Veterans General Hospital ( Site 0504), Taipei, Not set
Linkou Chang Gung Memorial Hospital ( Site 0502), Taoyuan, Not set
Basken Adana Dr.Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1103), Adana, Not set
Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1102), Ankara, Not set
Ankara Sehir Hastanesi ( Site 1108), Ankara, Not set
Istanbul Universitesi Istanbul Tip Fakultesi ( Site 1100), Istanbul, Not set
Medipol Universite Hastanesi ( Site 1104), Istanbul, Not set
Medical Park Izmir Hastanesi ( Site 1109), Izmir, Not set
Kocaeli Universitesi Tip Fakultesi ( Site 1106), Kocaeli, Not set
Inonu Universitesi Tip Fakultesi ( Site 1101), Malatya, Not set
Norfolk & Norwich University Hospital NHS Foundation Trust ( Site 1206), Norwich, Norfolk
University Hospital of North Staffordshire ( Site 1202), Stoke-On-Trent, Staffordshire
Ipswich Hospital ( Site 1207), Ipswich, Suffolk
St Bartholomew s Hospital ( Site 1205), London, Not set
The Royal Marsden Foundation Trust ( Site 1200), London, Not set
Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 1204), London, Not set
Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1208), Preston, Not set
University Hospital Southampton NHS Foundation Trust ( Site 1203), Southampton, Not set
Royal Marsden NHS Foundation Trust ( Site 1201), Sutton, Not set
Conditions: Head and Neck Neoplasms
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Completed
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT, CCS, ASPS, UPS, LMS and OS). Nine sites in Spain, 3 sites in Italy and 1 site in the United Kingdom.
Stage 1 (PHASE 1 and PHASE 2)
Objective: To determine the recommended dose of the sunitinib plus nivolumab combination for phase II part. To evaluate the efficacy of t... Read More
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT, CCS, ASPS, UPS, LMS and OS). Nine sites in Spain, 3 sites in Italy and 1 site in the United Kingdom.
Stage 1 (PHASE 1 and PHASE 2)
Objective: To determine the recommended dose of the sunitinib plus nivolumab combination for phase II part. To evaluate the efficacy of the sunitinib plus nivolumab combination as measured by the progression-free survival rate (PFSR) at 6 months in patients with advanced soft tissue and bone sarcomas.
Treatment: Adult patients will receive an initial induction phase (IP) from day 1 to day 14 of sunitinib 37.5 mg/day followed by a maintenance phase (MP) of sunitinib 37.5 mg/day continuously + nivolumab 3 mg/kg intravenous every 2 weeks infused over 1 hour. If three or more DLTs occur from day 15 to 42, for an initial set of 10 patients, sunitinib dose will be lowered to 25 mg/day or treatment schedule will be changed to 2 weeks on and one week off until recovery from toxicities.
Stage 2
C1 to 6
Objective: To evaluate the efficacy of the sunitinib plus nivolumab combination as measured by PFSR at 6 months (CS/DDCS, EMC, VS, SFT, CCS cohorts) and at 12 months (ASPS cohort).
Treatment: Adult patients will receive an initial induction phase (IP) from day 1 to day 14 of sunitinib 37.5 mg/day followed by a maintenance phase (MP) of sunitinib 25mg/day continuously + nivolumab 240mg every 2 weeks. Pediatric patients will receive an initial IP from day 1 to day 14 of (\<18 years) sunitinib at 25 mg/day unless the body surface area (BSA) of the patient is \>1.7. If BSA is \>1.7, then sunitinib 37.5 mg/day will be given followed by a MP of sunitinib 25 mg/day continuously + nivolumab 240 mg every 2 weeks regimen (if weight ≥40 kg) or sunitinib 25 mg/day continuously + nivolumab 3 mg/kg every 2 weeks regimen (if weight \<40kg).
C 7
Objective: To determine the MTD of the epirubicin + ifosfamide + nivolumab combination in undifferentiated pleomorphic sarcoma and of the doxorubicin + dacarbazine + nivolumab combination in leiomyosarcoma.
Treatment:Cohort 7a dose level 0: Patients will receive epirubicin dose of 60 mg/m2/d, d1 and d2 IV 20 minutes; followed by ifosfamide 3 g/m2/d d1-3, IV 3h with MESNA protection (40% of total dose of ifosfamide in each administration at 0, 3 and 6 h from ifosfamide initiation). Once finished Ifosfamide infusion of day 3, nivolumab is administered during 30 minutes, at dose of 360 mg IV, Q3W. GCSF support is mandatory. If three or more DLTs occur nivolumab dose will be lowered to dose level -1.
Cohort 7b dose level 0: Patients will receive doxorubicin at dose of 75 mg/m2/d, d1 IV 20 minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes. Dacarbazine is administered also on day 2 of cycle. Once finished Dacarbazine infusion of day 2, nivolumab is administered for 30 minutes, at dose of 360 mg IV, Q3W. GCSF support is mandatory. If three or more DLTs occur nivolumab dose will be lowered to dose level -1 where patients will receive doxorubicin at dose of 75 mg/m2/d, d1 IV 20 minutes; followed by dacarbazine 400 mg//m2/d IV 60 minutes. Dacarbazine is administered also on day 2 of cycle. Once finished dacarbazine infusion of day 2, nivolumab is administered for 30 minutes, at dose of 240 mg IV, Q3W. GCSF support is mandatory. One-year maintenance of nivolumab is foreseen in the absence of progressive disease.
C 8
Objectives:To determine the MTD of the MAP + nivolumab combination (phase I). Proportion of patients achieving good pathological response (phase II)
Treatment dose level 0: In the IP, patients will receive CDDP 120 mg/m2 in 48h IV infusion (days 1-2) followed by doxorubicin 75 mg/m2 in 48h IV infusion (days 3-4). CDDP and doxorubicin will be given on days 1-4 and 36-39. Nivolumab administration will start on day 4 at flat dose 240 mg (after the end of doxorubicin), being the following doses administered on days 18, 39, and 53 (240 mg). HD methotrexate at 12 g/m2 in 2-h infusion will be administered on days 22, 29, 57, and 64. Surgery will be performed after finishing IP. Adjuvant chemotherapy will be administered after surgery. During the MP patients will receive nivolumab on day 210, every two weeks up to day 364. If three or more DLTs occur, then nivolumab dose level -1 will be activated. Read Less
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
08/12/2024
Locations: Istituto Ortopedico Rizzoli, Bologna, Not set +12 locations
Istituto Ortopedico Rizzoli, Bologna, Not set
Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Not set
Istituto Nazionale dei Tumori, Milano, Not set
Hospital Universitario Fundación Jiménez Díaz, Madrid, Comunidad De Madrid
Complejo Hospitalario Universitario de Canarias, La Laguna, Santa Cruz De Tenerife
Hospital Universitari Vall d'Hebrón, Barcelona, Not set
Hospital de la Santa Creu i Sant Pau, Barcelona, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Universitario Virgen del Rocío, Sevilla, Not set
Hospital Universitari i Politècnic La Fe, Valencia, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
University College London Hospitals NHS Foundation Trust, London, Not set
Conditions: Soft Tissue Sarcoma, Bone Sarcoma
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Active Not Recruiting
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design. Read Less
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/26/2024
Locations: St Luke's Hospital, Dublin, Not set +37 locations
St Luke's Hospital, Dublin, Not set
St James's Hospital, Dublin, Not set
Royal Devon and Exeter Hospital, Exeter, Devon
Leicester Royal Infirmary, Leicester, East Midlands
Castle Hill Hospital, Cottingham, East Yorkshire
Colchester General Hospital, Colchester, Essex
Queen's Hospital, Romford, Essex
Royal Preston Hospital, Preston, Lancashire
James Cook University Hospital, Middlesbrough, North Yorkshire
York Hospital, York, North Yorkshire
Churchill Hospital, Oxford, Oxfordshire
Weston Park Hospital, Sheffield, South Yorkshire
Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear
Queen Elizabeth Hospital, Birmingham, West Midlands
University Hospital Coventry, Coventry, West Midlands
Newcross Hospital, Wolverhampton, West Midlands
Bradford Royal Infirmary, Bradford, West Yorkshire
St James's University Hospital, Leeds, West Yorkshire
Aberdeen Royal Infirmary, Aberdeen, Not set
Royal United Hospital, Bath, Not set
Belfast City Hospital, Belfast, Not set
Bristol Haematology and Oncology Centre, Bristol, Not set
Addenbrooke's Hospital, Cambridge, Not set
Velindre Cancer Centre, Cardiff, Not set
Cheltenham General Hospital, Cheltenham, Not set
Western General Hospital, Edinburgh, Not set
Beatson West of Scotland Cancer Centre, Glasgow, Not set
Aintree University Hospital, Liverpool, Not set
North Middlesex Hospital, London, Not set
Christie Hospital, Manchester, Not set
Norfolk and Norwich University Hospital, Norwich, Not set
Nottingham City Hospital, Nottingham, Not set
Derriford Hospital, Plymouth, Not set
Royal Shrewsbury Hospital, Shrewsbury, Not set
Singleton Hospital, Swansea, Not set
Musgrove Park Hospital, Taunton, Not set
Torbay Hospital, Torquay, Not set
Clatterbridge Cancer Centre, Wirral, Not set
Conditions: Oropharyngeal Cancer
109 - 120 of 298